contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nordic-nanovector-asa-invitation-to-second-half-and-full-year-2022-results-presentation-and-webcast

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Thor Medical is a pharmaceutical company. The company specializes in the development of antibody drugs for the treatment of hematological cancers. The greatest specialization is found in precision therapy used in the clinical phase. Other diseases treated are non-Hodgkin lymphoma (NHL). The company was founded in 2009 and is headquartered in Oslo, Norway.

Thor Medical

Oslo, Norway, 21 February 2023Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the second half and full year 2022 on Tuesday, 28 February 2023.A presentation ...

Oslo, Norway, 21 February 2023Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the second half and full year 2022 on Tuesday, 28 February 2023.A presentation by Nordic Nanovector's interim CEO &amp; CFO, Ludvik Sandnes, will be held in-person and webcast live beginning at 8:30am CET.VENUE: ADVOKATFIRMAET CLP DA, Sommerrogata 13, 0255 OsloQuestions can be submitted in advance to ir@nordicnanovector.comThe webcast can be accessed from www.nordicnanovector.com in the section: Investors &amp; Media and a recording will also be available on this page after the event.The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors &amp; Media/Reports and Presentation/Interim Reports/2022 from 7:00am CET the same day.IR enquiriesLudvik Sandnes, Interim CEO &amp; CFO +47 907 43 017ir@nordicnanovector.comAbout Nordic NanovectorNordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.Further information can be found at www.nordicnanovector.com&nbsp;(<a href="https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.nordicnanovector.com%2F&amp;data=05%7C01%7Cmark.swallow%40medistrava.com%7C0b5d55887fcc4bddd24108db03d8d2c1%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7C0%7C638108002017583559%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=8ttx4sNkxIXKbRtEA7RQp%2FvHln24QCaKkOEaehniofM%3D&amp;reserved=0">https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.nordicnanovector.com%2F&amp;data=05%7C01%7Cmark.swallow%40medistrava.com%7C0b5d55887fcc4bddd24108db03d8d2c1%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7C0%7C638108002017583559%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=8ttx4sNkxIXKbRtEA7RQp%2FvHln24QCaKkOEaehniofM%3D&amp;reserved=0</a>)This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

Nordic Nanovector ASA: Invitation to Second Half and Full Year 2022 Results Presentation and Webcast